Leveraging AI, OpenDNA’s tests analyse the DNA of a person alongside clinical attributes. Credit: New Africa / Shutterstock.

Primary care provider Harper Health has collaborated with genetic health solutions provider OpenDNA to offer patients access to polygenic and monogenic screening.

This partnership aims to deliver insights into cancer, cardiovascular, and other health condition risks through OpenDNA’s suite of tests, TotalRisk+, CardioRisk+, and CancerRisk+.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Leveraging AI technology, these tests analyse a person’s DNA alongside clinical attributes, evaluating their risk for various health conditions.

The outcomes are analysed using AI models and integrated into the electronic medical record (EMR) and physician workflow via an interactive user interface.

The information collected from the tests will allow individuals and healthcare providers to make “informed” decisions regarding lifestyle modifications, treatment alternatives, and preventive care.

The tests encompass both monogenic risks, stemming from a single gene; and polygenic risks, influenced by several genes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The TotalRisk+ test includes monogenic cancer screening and the CardioRisk+ test specifically assesses the risk for cardiovascular conditions, including heart attacks and diabetes. CancerRisk+ screens for several types of cancer, including prostate, colon, and breast cancer.

Individuals at Harper Health can now undergo these genetic screening tests with a cheek swab process with the help of their physician.

Outcomes are expected within two weeks, after which Harper Health physicians will assist individuals in interpreting the findings and creating “personalised” health plans, depending on their risk profiles.

Harper Health CEO and founder Dr William Harper said: “By partnering with OpenDNA, we can now offer genetic screening that empowers our patients to take proactive steps towards managing their health and preventing future illness.

“Understanding individual risk profiles enables our physicians to provide more targeted and effective preventive care recommendations.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact